



PATENT 2460-1-001

IN THE UNITED STAT AND TRADEMARK OFFICE

APPLICANT:

AMANDA REYNOLDS-JAHODA ET AL.

SERIAL NO. :

09/463,174

EXAMINER:

UNKNOWN

FILED

JANUARY 18, 2000

ART UNIT :

3734

FOR

GENE THERAPY VEHICLE COMPRISING DERMAL SHEATH

TISSUE

Certificate of Mailing Under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231 on April 26, 2000.

Michael D. Davis, Reg. No. 39,161 (Name of Registered Rep.)

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

Sir:

Enclosed is a copy of the Official Filing Receipt marked in Fred to show the correction that is needed. The correction is as follows.

The name of the Applicants should be changed from

"AMANDA REYNOLDS-JAHODA" and "COLIN ALBERT BUCHANAN IAHODA" to - - AMANDA REYNOLDS-JAHODA-- and - - COLIN ALBERT BUCHANAN JAHODA--

as it appears in the Declaration and the Verified Statement Claiming Small Entity that was filed on January 18, 2000. A copy of said Declaration and the Verified Statement "TECETURE"
"MAIL 8004 Claiming Small Entity is enclosed.

Issuance of a corrected Official Filing Receipt is respectfully requested.

Respectfully submitted,

MICHAEL D. DAVIS Attorney for Applicant(s) Registration No. 39,161

KLAUBER & JACKSON 411 Hackensack Avenue Hackensack, New Jersey 07601 (201) 487-5800

Date: April 26, 2000

FILING RECEIPT *OC000000005038087*



UNITED STATES DEPARTMENT OF COMMERCE Pat nt and Trademark Offic

Address: ASSISTANT SECRETARY AND COMMISSIONER OF PATENT AND TRADEMARKS Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/463.174	01/18/2000	3734	564	2460-1-001	11	36	3

DAVID A JACKSON
KLAUBER & JACKSON
A11 HACKENSACK AVENUE
4TH FLOOR
HACKENSACK, NJ 07601
MAY

APR 2.0 2000

KLAUBER & JACKSON

APR 2.0 2000

KLAUBER & JACKSON

Date Mailed: 04/07/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Servic C nter. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "N tice to File Missing Parts" for this application, please submit any corrections to this Filing Rec ipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate an ther Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

AMANDA REYNOLDS JAHODA, RICHMOND, NORTH YORKSHIRE, UNITED KINGDOM; COLIN ALBERT BUCHANAN IAHODA, RICHMOND, NORTH YORKSHIRE, UNITED KINGDOM;

C ntinuing Data as Claimed by Applicant

THIS APPLICATION IS A 371 OF PCT/GB98/02150 07/17/1998

F reign Applications

UNITED KINGDOM 9715085.8 07/18/1997

If Required, Foreign Filing License Granted 04/07/2000

Title

GENE THERAPY VEHICLE COMPRISING DERMAL SHEATH TISSUE

Preliminary Class

604

Data entry by: BARRETO, NGA

Team: OIPE

Date: 04/07/2000

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Cod , S ction 184 Title 37, Code of F deral R gulations, 5.11 & 5./15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They
- are considered to be unnecessary to the understanding of the title.

 The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.

 The title may be truncated if it consists of more than 600 characters (letters and spaces combined).

- The docket number allows a maximum of 25 characters.
 If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination **Customer Service Center** Washington, DC 20231